Eton’s FDA rejection leads July cornea news

Cornea-related news in the month of July included FDA and clinical trial updates, but the most-read cornea story on was the FDA’s rejection of Eton Pharmaceuticals’ allergic conjunctivitis treatment candidate EM-100.
Here are the top five cornea stories of the month:
FDA rejects Eton's allergic conjunctivitis drop
Eton’s partner, Bausch Health Companies, which acquired the U.S. rights to EM-100 in February, received a complete response letter from the FDA regarding the filing. Read more.
Cequa more effective than vehicle in treating dry eye<

Full Story →